Synthesis, Characterization, In-Vitro Antimicrobial Evaluation and Molecular Docking Studies of Aromatic Aldehydes Substituted Thiosemicarbazide Quinoxaline Derivatives
-
El-Sharief MAMS, Abbas SY, El-Bayouki KAM, E. W. El-Gammal EW. Synthesis of thiosemicarbazones derived from N-(4-hippuric acid)thiosemicarbazide and different carbonyl compounds as antimicrobial agents.Eur J Med Chem. 2013; 67:263–68.
-
Tenover FC.Mechanisms of antimicrobial resistance in bacteria. Am J Inf Cont. 2006; 34 Suppl 5:S3–S10.
-
Katritzky AR, Rees CW, editors. The structure, reactions, synthesis, and uses of heterocyclic compounds.Comprehensive Heterocyclic Chemistry. 1st ed. Oxford UK: Pergamon Press;1984:157–97.
-
Ganapaty S, Ramalingam P,Rao CB. Antibacterial, antifungal and antitubercular screening of some novel condensed bridgehead nitrogen heterocycles of quinoxalines. Ind J Hetero Chem. 2007; 16:283-86.
-
Refaat HM, Moneer AA, Khalil OM. Synthesis and antimicrobial activity of certain novel quinoxalines. Arch Phram Res. 2004; 27:1093-98.
-
Badran MM, Abouzid KAM, Hussein MHM. Synthesis of certain substituted quinoxalines as anti-microbial agents. Part II.Arch Pharm Res. 2003; 26:107–13.
-
Tandon VK, Yadav DB, Maurya HK, Chaturvedi AK,Shukla PK. Design, synthesis and biological evaluation of 1,2,3- trisubstituted-1,4- dihydrobenzo [g] quinoxaline-5,10-diones and related compounds as antifungal and antibacterial agents. Bioorg Med Chem. 2006; 14(17):6120-126.
-
Sanna P, Carta A, Loriga M, Zanetti S, Sechi L. Preparation and biological evaluation of 6/7-trifluoromethyl (nitro)-6,7-difluoro-3-alkyl(aryl)-substituted-quinoxalin-2-ones. Part III Farmaco. 1999; 54(3):1169-177.
-
Jaso A, Zarranz B, Aldana I, Monge A. Synthesis of new 2-acetyl and 2-benzoyl quinoxaline 1,4-di-N-oxide derivatives Asanti-mycobacterium tuberculosis agents. Eur J Med Chem. 2003; 38:791–800.
-
Rangisetty JB, Gupta CNVHB, Prasad AL, Srinivas P, Sridhar N, Parimoo P, et al. Synthesis of new-arylamino quinoxalines and their antimalarial activity in mice. J Pharm Pharmacol. 2001; 53(10):1409–13.
-
Crowther AF, Curd FHS, Davey DG, Stacey GJ. Synthetic antimalarials, Part 39 Dialkylaminoalkyl-aminoquinoxalines. J Chem Soc. 1949:1260–62.
-
Guillon J, Forfar I, Matsuda MM, Desplat V, Saliege M, Thiolat D. Synthesis, analytical behaviour and biological evaluation of new 4-substituted pyrrolo[1,2-a]quinoxalines as antileishmanial agents.Bioorg Med Chem Lett. 2007; 15:194-210.
-
Carta A, Sanna P, Gherardini, Usai D, Zanetti S. Novel functionalized pyrido[2,3-9]-quinoxalinones as antibacterial, antifungal and anticancer agents. II Farmaco. 2001; 56(12):933–38.
-
Sanna P, Carta A, Loriga M, Zanetti S, Sechi L. Synthesis of 3,6,7-substituted quinoxalin- 2-ones for evaluation of the antimicrobial and anticancer activity. Part: II Farmaco.1999; 54(3):161-68.
-
Hassan SY, Khattab SN, BekhitAA, Amer A. Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors.Bioorg Med Chem Lett. 2006; 16(6):1753-56.
-
Sarges R, Howard HR, Browne RG, Lebel LA, Seymour PA, Koe BK. 4- Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J Med Chem. 1990; 33(8):2240-54.
-
Burguete A, Pontiki E, Hadjipavlou-Litina VD.Synthesis and anti-inflammatory/antioxidant activities of some new ring-substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and of their 4,5-dihydro-(1H)-pyrazole analogues.Bioorg Med Chem Lett. 2007; 17(23): 6439-43.
-
Santivañez-Veliz M, Pérez-Silanes S, Torres E, Moreno-Viguri E. Hypoxia-Selective Agents Derived from Quinoxaline 1,4-Di-N-oxides. Bioorg Med Chem Lett. 2016; 26(9): 2188-93.
-
Ries UJ, Priekpe HW, Havel NH, Handschuh S, Mihm G, Stassen JM, et al. Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as a novel, potent antithrombotic agents. Bioorg Med Chem Lett. 2003; 13:2297-02.
-
Palluotto F, Sosic A, Pinato O, Zoidis G, Catto M, SissiC, et al.Quinolino[3,4-b]quinoxalines and pyridazino[4,3-c]quinoline derivatives: Synthesis, inhibition of topoisomerase IIα, G-quadruplex binding and cytotoxic properties. Eur J Med Chem. 2016; 123:704-717.
-
Beraldo H, Gambino D. The wide pharmacological versatility of semi carbazones, thiosemicarba-zones and their metal complexes. Mini-Rev Med Chem. 2004;4(1):31–39.
-
Ramachandran R, Rani M, Kabilan S. Design, synthesis and biological evaluation of novel 2-[(2, 4-diaryl-3-azabicyclo [3.3. 1] nonan-9-ylidene) hydrazono]-1, 3-thiazolidine-4-ones as a new class of antimicrobial agents. Bioorg Med Chem Lett. 2009; 19(10): 2819–23.
-
Shipman Jr C, Smith SH, Drach JC, Klayman DL. Antiviral Activity of 2-Acetylpyridine Thiosemicarbazones Against Herpes Simplex Virus. Antimic Agen Chem. 1981; 19(4):682-85.
-
Quenelle DC, Keith KA, Kern ER. In-vitro and in-vivo evaluation of isatin-β-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. Antiv Res. 2006;71(1):24–30.
-
Afrasiabi Z, Sinn E, Padhye S. Transition metal complexes of phenanthrenequinone thiosemicarbazone as potential anticancer agents: synthesis, structure, spectroscopy, electrochemistry and in-vitro anticancer activity against human breast cancer cell-line, T47D. J Inorg Biochem. 2003;95(4):306–14.
-
Singh N, Srivastava A, Sodhi A, Ranjan P. In- vitro and in- vivo antitumor studies of a new thiosemicarbazide derivative and its complexes with 3d-metal ions. Trans Met Chem 2000;25:133–40.
-
Yousef TA, Badria FA, Ghazy SE, El-Gammal OA, Abu El-Reash GM. In-vitro and in-vivo antitumor activity of some synthesized 4-(2-pyridyl)-3-Thiosemicarbazides derivatives. Inter J Med Sci. 2011;3(2):37–46.
-
Singh S, Bharti N, Naqvi F, Azam A. Synthesis, characterization and in-vitro antiamoebic activity of 5 nitrothiophene-2-carboxaldehyde thiosemicarbazones and their Palladium(II) and Ruthenium(II) complexes. Eur J Med Chem. 2004;39(5):459–65.
-
Sharma S, Athar F, Maurya MR, Naqvi F, Azam A. Novel bidentate complexes of Cu (II) derived from 5-nitrofuran-2-carboxaldehyde thiosemicarbazones with antiamoebic activity against E. histolytica. Eur J Med Chem. 2005;40(12):557–62.
-
Illan-Cabeza NA, Hueso-Urena F, Moreno-Carretero MN, MartinezMartos JM, Ramirez-Exposito MJ. Synthesis, Characterization and Antiproliferative Activity of Metal Complexes with the Schiff Base Derived from the Condensation 1:2 of 2,6-Diformyl-4- Methylphenol and 5,6-Diamino-1,3-Dimethyluracil. J InorgBiochem. 2008; 102:647–55.
-
Naveen VK, Vidyanand KR, Kirasur BN. Mallinath HH. Transition metal complexes of thiosemicarbazones with quinoxaline hub: an emphasis on antidiabetic property. Med Chem Res. 2012; 21(5):663–71.
-
Bal TR, AnandB, Yogeeswari P, Sriram D. Synthesis and evaluation of the anti-HIV activity of isatin beta-thiosemicarbazone derivatives. Bioorg Med Chem Lett. 2005; 15 (20):4451-55.
-
Ukrainets IV, Tkach AA, Grinevich LA, Turov AV, Bevz OV. 4-Hydroxy-2-quinolones 165.1-R-4-hydroxy-2-oxo-1,2-dihydro-quinoline-3-carbaldehydes and their thiosemicarbazones, Synthesis, structure, and biological properties. Chem Hetero Comp. 2009; 45:705–14.
-
Mohamed NA, Mohamed RR, Seoudi RS. Synthesis and characterization of some novel antimicrobial thiosemicarbazone O-carboxymethyl chitosan derivatives. Int J BioMacromol. 2014; 63:163–69.
-
Siddiqui N, Singh O. Antibacterial activity of some 4-N-substituted thiosemicarbazides and thiosemicarbazones. Ind J Pharm Sci. 2003; 65(4):423-25.
-
Parul N, Subhangkar N, Arun M. Antimicrobial activity of different thiosemicarbazone compounds against microbial pathogens. Int Res J Pharm. 2013; 3(5):351–63.
-
Siwek A, Stefanska J, Dzitko K, Ruszezak A. Antifungal effect of 4-arylthio semicarbazides against Candida species. Search for the molecular basis of antifungal activity of thiosemicarbazide derivatives. J Mol Model. 2012; 18(9):4159-70.
-
Naeem A, Badshah SL, Muska M, Ahmad N. Khan K. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity. Molecules. 2016; 21(4):268.
-
Esteves-Souza A. Rodrigues-Santos CE, Del Cistia CN, Silva DR, Sant’anna CM, Echevarria A. Solvent-free synthesis, DNA-topoisomerase II activity and molecular docking study of new asymmetrically N, N’-substituted ureas. Molecules. 2012; 17: 12882–94.
-
Tanitame A, Oyamada Y, Ofuji K, Fujimoto M, Suzuki K, Ueda T, Terauchi H, Kawasaki M, et al. Synthesis and antibacterial activity of novel and potent DNA gyrase inhibitors with azole ring. Bioorg Med Chem. 2004; 12(21):5515–24.
-
Azimvand J. Synthesis of new triazole and oxadiazole containing compound in the azide reaction as an antibacterial drug.J Chem Pharma Res. 2012; 4(8):3900-04.
-
Efthimiou EK, Thomadaki H, Sanakis Y, Raptopoulou CP, Katsaros N, Scorilas A, et al. Structure and biological properties of the copper(II) complex with the quinolone antibacterial drug N-propyl-norfloxacin and 2,20 -bipyridine. J InorgBiochem. 2007; 101:64–73.
-
El Shehry MF, Ghorab MM, Abbas SY, Fayed EA, Shedid SA, Ammar YA. Quinoline derivatives bearing pyrazole moiety: Synthesis and biological evaluation as possible antibacterial and antifungal agents. Eur J Med Chem. 2017; 143:1463–73.
-
Paneth A, Staczek P, Plech T, Dzitko K, Wujec M, Kusmierz E, et al. Biological evaluation and molecular modelling study of thiosemicarbazide derivatives as bacterial type IIA topoisomerase inhibitors. J EnzymInhib Med Chem. 2016;31:14-22.
-
Siwek A, Staczek P, Wujec M, Stefanska J, Kosikowska U, Malm A, et al. Biological and docking studies of topoisomerase IV inhibition of thiosemicarbazides. J Mol Model.2011; 17:2297-03.
-
Mohi El-Deen EM, Abd El-Meguid EA, Hasabelnaby S, Karam EA, Nossier ES. Synthesis, docking studies and in vitro evaluation of some novel theinopyridines and fused theinopyridine-quinolines as antibacterial agents and DNA gyrase inhibitors. Molecules.2019; 24(20):36-50.
-
Bellon S, Parsons JD, Wei Y, Hayakawa K, Swenson LL, Charifson PS, et al. Crystal structure of E. coli topoisomerase IV ParE subunit (24 and 43 kilodalton): A single residue decades differences in novobiocin in potency against topoisomerase IV and DNA gyrase.Antimicrob Agents Chemot. 2004; 48(5):1856-64.
-
European Committee for antimicrobial susceptibility testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Determination of minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution. Clin Microb Infect. 2000; 6(9):509-515.